Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
According to our Researcherlatest study, the global Amyotrophic Lateral Sclerosis (ALS) market size was valued at USD 308.7 million in 2023 and is forecast to a readjusted size of USD 366.6 million by 2030 with a CAGR of 2.5% during review period.
Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.
The cause is not known in 90% to 95% of cases. The remaining 5–10% of cases are inherited from a person's parents. About half of these genetic cases are due to one of two specific genes. The underlying mechanism involves damage to both upper and lower motor neurons. The diagnosis is based on a person's signs and symptoms, with testing done to rule out other potential causes.
The amyotrophic lateral sclerosis (ALS) therapeutics market is driven by the increasing prevalence of ALS and the growing demand for effective treatments to slow disease progression and improve patient outcomes. As the understanding of ALS pathophysiology improves, researchers and pharmaceutical companies are actively exploring novel therapeutic approaches, including gene therapies and immune-modulating agents. The approval of new ALS drugs and the development of combination therapies further propel market growth. However, challenges include the complexity of ALS as a multi-factorial disease, the difficulty in diagnosing ALS at an early stage, and the high cost of drug development and clinical trials. Addressing these challenges through collaborative research, improved diagnostic tools, and accessible treatment options will be crucial for the sustained growth of the ALS therapeutics market.
The Global Info Research report includes an overview of the development of the Amyotrophic Lateral Sclerosis (ALS) industry chain, the market status of Hospital (Riluzole, Edaravone (Radicava)), Drugs Store (Riluzole, Edaravone (Radicava)), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Amyotrophic Lateral Sclerosis (ALS).
Regionally, the report analyzes the Amyotrophic Lateral Sclerosis (ALS) markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Amyotrophic Lateral Sclerosis (ALS) market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Amyotrophic Lateral Sclerosis (ALS) market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Amyotrophic Lateral Sclerosis (ALS) industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Unit), revenue generated, and market share of different by Type (e.g., Riluzole, Edaravone (Radicava)).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Amyotrophic Lateral Sclerosis (ALS) market.
Regional Analysis: The report involves examining the Amyotrophic Lateral Sclerosis (ALS) market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Amyotrophic Lateral Sclerosis (ALS) market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Amyotrophic Lateral Sclerosis (ALS):
Company Analysis: Report covers individual Amyotrophic Lateral Sclerosis (ALS) manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Amyotrophic Lateral Sclerosis (ALS) This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospital, Drugs Store).
Technology Analysis: Report covers specific technologies relevant to Amyotrophic Lateral Sclerosis (ALS). It assesses the current state, advancements, and potential future developments in Amyotrophic Lateral Sclerosis (ALS) areas.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Amyotrophic Lateral Sclerosis (ALS) market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
Riluzole
Edaravone (Radicava)
Other
Market segment by Application
Hospital
Drugs Store
Other
Mitsubishi Tanabe Pharma
Sanofi
Mylan Pharma
Apotex
Glemark Generics
Covis Pharma
Sun Pharma
Lunan Pharma
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter 1, to describe Amyotrophic Lateral Sclerosis (ALS) product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Amyotrophic Lateral Sclerosis (ALS), with price, sales, revenue and global market share of Amyotrophic Lateral Sclerosis (ALS) from 2019 to 2024.
Chapter 3, the Amyotrophic Lateral Sclerosis (ALS) competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Amyotrophic Lateral Sclerosis (ALS) breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2023.and Amyotrophic Lateral Sclerosis (ALS) market forecast, by regions, type and application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Amyotrophic Lateral Sclerosis (ALS).
Chapter 14 and 15, to describe Amyotrophic Lateral Sclerosis (ALS) sales channel, distributors, customers, research findings and conclusion.
Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.
The cause is not known in 90% to 95% of cases. The remaining 5–10% of cases are inherited from a person's parents. About half of these genetic cases are due to one of two specific genes. The underlying mechanism involves damage to both upper and lower motor neurons. The diagnosis is based on a person's signs and symptoms, with testing done to rule out other potential causes.
The amyotrophic lateral sclerosis (ALS) therapeutics market is driven by the increasing prevalence of ALS and the growing demand for effective treatments to slow disease progression and improve patient outcomes. As the understanding of ALS pathophysiology improves, researchers and pharmaceutical companies are actively exploring novel therapeutic approaches, including gene therapies and immune-modulating agents. The approval of new ALS drugs and the development of combination therapies further propel market growth. However, challenges include the complexity of ALS as a multi-factorial disease, the difficulty in diagnosing ALS at an early stage, and the high cost of drug development and clinical trials. Addressing these challenges through collaborative research, improved diagnostic tools, and accessible treatment options will be crucial for the sustained growth of the ALS therapeutics market.
The Global Info Research report includes an overview of the development of the Amyotrophic Lateral Sclerosis (ALS) industry chain, the market status of Hospital (Riluzole, Edaravone (Radicava)), Drugs Store (Riluzole, Edaravone (Radicava)), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Amyotrophic Lateral Sclerosis (ALS).
Regionally, the report analyzes the Amyotrophic Lateral Sclerosis (ALS) markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Amyotrophic Lateral Sclerosis (ALS) market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Amyotrophic Lateral Sclerosis (ALS) market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Amyotrophic Lateral Sclerosis (ALS) industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Unit), revenue generated, and market share of different by Type (e.g., Riluzole, Edaravone (Radicava)).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Amyotrophic Lateral Sclerosis (ALS) market.
Regional Analysis: The report involves examining the Amyotrophic Lateral Sclerosis (ALS) market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Amyotrophic Lateral Sclerosis (ALS) market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Amyotrophic Lateral Sclerosis (ALS):
Company Analysis: Report covers individual Amyotrophic Lateral Sclerosis (ALS) manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Amyotrophic Lateral Sclerosis (ALS) This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospital, Drugs Store).
Technology Analysis: Report covers specific technologies relevant to Amyotrophic Lateral Sclerosis (ALS). It assesses the current state, advancements, and potential future developments in Amyotrophic Lateral Sclerosis (ALS) areas.
Competitive Landscape
: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Amyotrophic Lateral Sclerosis (ALS) market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Amyotrophic Lateral Sclerosis (ALS) market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
Riluzole
Edaravone (Radicava)
Other
Market segment by Application
Hospital
Drugs Store
Other
Major players
coveredMitsubishi Tanabe Pharma
Sanofi
Mylan Pharma
Apotex
Glemark Generics
Covis Pharma
Sun Pharma
Lunan Pharma
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Amyotrophic Lateral Sclerosis (ALS) product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Amyotrophic Lateral Sclerosis (ALS), with price, sales, revenue and global market share of Amyotrophic Lateral Sclerosis (ALS) from 2019 to 2024.
Chapter 3, the Amyotrophic Lateral Sclerosis (ALS) competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Amyotrophic Lateral Sclerosis (ALS) breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2023.and Amyotrophic Lateral Sclerosis (ALS) market forecast, by regions, type and application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Amyotrophic Lateral Sclerosis (ALS).
Chapter 14 and 15, to describe Amyotrophic Lateral Sclerosis (ALS) sales channel, distributors, customers, research findings and conclusion.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
